

Transaction Contacts



SVB Securities Serves as Joint Bookrunner Replimune for Replimune's (Nasdaq: REPL) \$225 Million Follow-On Offering

man (dyn Jack Berlinsen

Launched a publicly marketed transaction on December 7th (post-close) and priced on December 8th (post-

- Well oversubscribed from both new and existing investors Base deal upsized from \$125 million to \$225 million.
- Consisted of 5.374.486 shares of common stock at a price of \$23.56 per share, representing a 1.8% premium.
- to branch and a 2.3% discount to bed sale, as well as pre-funded warrants at a price of \$23,4599 per warrant Resimune intends to use the net proceeds, transfer with its existing cash and cash equivalents, short-term.
 - investments and proseeds from its available term loan facility to fund preparations for the commercial launch descriptions of common and below product consistency based on the commutery RP's stafform, and by conseq.
- This is 5VB Securities 5th booksun offering for Replimune and 48th booksun equity affering in 2022.